LU91293I2 - Maropitant ou un sel pharmaceutiquement acceptabled'un tel composé, y compris le sel de monohydrate de citrate. cerenia - Google Patents

Maropitant ou un sel pharmaceutiquement acceptabled'un tel composé, y compris le sel de monohydrate de citrate. cerenia

Info

Publication number
LU91293I2
LU91293I2 LU91293C LU91293C LU91293I2 LU 91293 I2 LU91293 I2 LU 91293I2 LU 91293 C LU91293 C LU 91293C LU 91293 C LU91293 C LU 91293C LU 91293 I2 LU91293 I2 LU 91293I2
Authority
LU
Luxembourg
Prior art keywords
cerenia
maropitant
salt
compound
pharmaceutically acceptable
Prior art date
Application number
LU91293C
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91293(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of LU91293I2 publication Critical patent/LU91293I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU91293C 1991-05-31 2006-12-06 Maropitant ou un sel pharmaceutiquement acceptabled'un tel composé, y compris le sel de monohydrate de citrate. cerenia LU91293I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31
PCT/US1992/003317 WO1992021677A1 (fr) 1991-05-31 1992-04-28 Derives de quinuclidine

Publications (1)

Publication Number Publication Date
LU91293I2 true LU91293I2 (fr) 2007-02-06

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91293C LU91293I2 (fr) 1991-05-31 2006-12-06 Maropitant ou un sel pharmaceutiquement acceptabled'un tel composé, y compris le sel de monohydrate de citrate. cerenia

Country Status (41)

Country Link
US (3) US5807867A (fr)
EP (1) EP0587723B1 (fr)
JP (2) JPH0733386B2 (fr)
KR (1) KR100214905B1 (fr)
CN (1) CN1048492C (fr)
AP (1) AP299A (fr)
AT (1) ATE135006T1 (fr)
AU (1) AU657552B2 (fr)
BG (1) BG61694B1 (fr)
BR (1) BR9206073A (fr)
CA (1) CA2102179C (fr)
CZ (1) CZ281403B6 (fr)
DE (4) DE122006000066I1 (fr)
DK (1) DK0587723T3 (fr)
EG (1) EG19944A (fr)
ES (1) ES2084361T3 (fr)
FI (1) FI114475B (fr)
GR (1) GR3019687T3 (fr)
GT (1) GT199200028A (fr)
HU (1) HU217548B (fr)
IE (1) IE72473B1 (fr)
IL (1) IL102008A (fr)
IS (1) IS1611B (fr)
LU (1) LU91293I2 (fr)
MA (1) MA22539A1 (fr)
MX (1) MX9202554A (fr)
NL (1) NL300250I2 (fr)
NO (2) NO302701B1 (fr)
NZ (2) NZ242956A (fr)
OA (1) OA09867A (fr)
PL (1) PL171379B1 (fr)
PT (1) PT100546B (fr)
RO (1) RO110499B1 (fr)
RU (1) RU2103269C1 (fr)
SK (1) SK390692A3 (fr)
TW (1) TW204349B (fr)
UA (1) UA27776C2 (fr)
UY (1) UY23422A1 (fr)
WO (1) WO1992021677A1 (fr)
YU (1) YU48995B (fr)
ZA (1) ZA923942B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK390692A3 (en) * 1991-05-31 1998-02-04 Pfizer Quinuclidine derivatives, preparation method thereof and use
DK0589924T3 (da) * 1991-06-20 1996-09-30 Pfizer Fluoralkoxybenzylaminoderivater af nitrogenholdige heterocyclusser
DE69331103T2 (de) * 1992-08-19 2002-03-14 Pfizer Inc., New York Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
ATE147385T1 (de) * 1992-11-12 1997-01-15 Pfizer Chinuclidin derivat als substanz p antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (fr) * 1993-11-17 1995-10-11 Pfizer Antagonistes de la substance P pour le traitement et la prévention de l'erythème solaire.
EP0659409A3 (fr) * 1993-11-23 1995-08-09 Pfizer Antagonistes de la substance P pour l'inhibition de l'angiogénése.
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
AU751114B2 (en) * 1998-03-19 2002-08-08 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use as tachykinin receptor antagonists
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP1299393A2 (fr) 2000-07-11 2003-04-09 Bristol-Myers Squibb Pharma Company Tetrahydroisoquinoleines 4-phenyle substituees et leur utilisation therapeutique
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (fr) * 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
EP1411946A1 (fr) * 2001-07-20 2004-04-28 Pfizer Products Inc. Utilisation d'antagonistes du recepteur nk-1 pour modifier un comportement indesirable chez des chiens, des chats et des chevaux
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2005045395A2 (fr) * 2003-10-27 2005-05-19 Meyer Donald W Methode de detection de l'encephalopathie spongiforme bovine
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
RU2337685C2 (ru) 2004-01-30 2008-11-10 Пфайзер Продактс Инк. Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза
US8183230B2 (en) * 2004-01-30 2012-05-22 Pfizer Inc. Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
ES2296131T3 (es) * 2004-02-02 2008-04-16 Pfizer Products Incorporated Procedimiento para la preparacion de 1-(2s,3s)-2-bencidril-n-(5-terc-butil-2-metoxibencil)quinuclidin-3-amina.
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
EP1940842B1 (fr) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
EP2145884B1 (fr) 2007-04-02 2014-08-06 Msd K.K. Dérivé d'indoledione
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2429293B1 (fr) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company FORMES CRISTALLINES DE (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN -6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE ET LEURS UTILISATIONS
EP2429295B1 (fr) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation
WO2010132442A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CA2805265A1 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian)
CA2807307C (fr) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani)
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
EP2615916B1 (fr) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
MX2019012088A (es) 2017-04-10 2020-02-07 Chase Therapeutics Corp Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias.
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
EP3645120A4 (fr) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
EP3706747A4 (fr) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3758688B1 (fr) 2018-02-26 2024-03-27 Ospedale San Raffaele S.r.l. Antagonistes nk-1 destinés à être utilisés dans le traitement de la douleur oculaire
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
EP3833668A4 (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
CA2084193C (fr) * 1990-06-01 1998-04-07 John A. Lowe, Iii 3-amino-2-arylquinuclidines
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
SK390692A3 (en) * 1991-05-31 1998-02-04 Pfizer Quinuclidine derivatives, preparation method thereof and use
EP0919245A3 (fr) * 1991-09-20 2000-11-15 Glaxo Group Limited Un recepteurs antagoniste NK-1 et un corticosteroide antiinflammatoire systemique, pour le traitement des vomissements
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ATE194342T1 (de) * 1996-01-19 2000-07-15 Lonza Ag Verfahren zur herstellung von optisch aktivem 3- chinuclidinol
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
HU217548B (hu) 2000-02-28
US6222038B1 (en) 2001-04-24
RO110499B1 (ro) 1996-01-30
CZ281403B6 (cs) 1996-09-11
FI114475B (fi) 2004-10-29
PT100546A (pt) 1993-08-31
AU657552B2 (en) 1995-03-16
DE9290063U1 (de) 1994-02-24
JP2645225B2 (ja) 1997-08-25
HU9303393D0 (en) 1994-03-28
EG19944A (en) 1997-02-27
ATE135006T1 (de) 1996-03-15
IL102008A0 (en) 1992-12-30
DE69208877D1 (de) 1996-04-11
SK278788B6 (sk) 1998-02-04
CN1048492C (zh) 2000-01-19
US5939433A (en) 1999-08-17
DE69208877T2 (de) 1996-07-25
YU48995B (sh) 2003-04-30
EP0587723B1 (fr) 1996-03-06
CA2102179A1 (fr) 1992-12-01
SK390692A3 (en) 1998-02-04
PL171379B1 (en) 1997-04-30
MA22539A1 (fr) 1992-12-31
PT100546B (pt) 1999-12-31
CZ390692A3 (en) 1994-02-16
BG98248A (bg) 1994-07-29
CA2102179C (fr) 1998-10-27
US5807867A (en) 1998-09-15
IS3871A (is) 1992-12-02
NO934312D0 (no) 1993-11-29
KR100214905B1 (ko) 1999-08-02
JPH0733386B2 (ja) 1995-04-12
OA09867A (en) 1994-08-15
MX9202554A (es) 1992-11-01
FI935297A0 (fi) 1993-11-29
IE72473B1 (en) 1997-04-23
WO1992021677A1 (fr) 1992-12-10
DE122006000066I2 (de) 2007-12-06
NO302701B1 (no) 1998-04-14
NO2007003I1 (no) 2007-03-26
IS1611B (is) 1996-10-18
GT199200028A (es) 1993-11-20
TW204349B (fr) 1993-04-21
AP9200384A0 (en) 1992-07-31
CN1067428A (zh) 1992-12-30
AU1990192A (en) 1993-01-08
ZA923942B (en) 1993-11-29
UY23422A1 (es) 1992-11-12
UA27776C2 (uk) 2000-10-16
GR3019687T3 (en) 1996-07-31
NO934312L (no) 1993-11-29
NL300250I1 (nl) 2007-02-01
NZ242956A (en) 1995-06-27
DE122006000066I1 (de) 2007-03-22
NL300250I2 (nl) 2007-03-01
IE921729A1 (en) 1992-12-02
HUT70151A (en) 1995-09-28
NZ270673A (en) 1997-07-27
JPH07285965A (ja) 1995-10-31
ES2084361T3 (es) 1996-05-01
NO2007003I2 (no) 2011-04-18
JPH06504292A (ja) 1994-05-19
EP0587723A1 (fr) 1994-03-23
RU2103269C1 (ru) 1998-01-27
FI935297A (fi) 1993-11-29
YU56492A (sh) 1995-03-27
IL102008A (en) 1995-12-08
DK0587723T3 (da) 1996-04-01
BG61694B1 (bg) 1998-03-31
AP299A (en) 1994-01-14
BR9206073A (pt) 1994-12-06

Similar Documents

Publication Publication Date Title
LU91293I2 (fr) Maropitant ou un sel pharmaceutiquement acceptabled'un tel composé, y compris le sel de monohydrate de citrate. cerenia
PH31658A (en) Pharmaceutically active cns compounds.
EP0342541A3 (fr) Inhibiteurs de protéases rétrovirales
HK1034645A1 (en) Fungicidal active compound combinations.
DE59300018D1 (de) Fungizide Azolylmethyl-fluorcycloproplylderivate.
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
CA2040248A1 (fr) Methode d'inhibition de la secretion d'acide gastrique
EP0671925A4 (fr) Composes therapeutiques derives du margousier.
GB9225131D0 (en) Fungicidal active compound combinations
DE69017970D1 (de) Biozide Verbindungen.
EP0649308A4 (fr) Prevention de l'hemolyse.
ZA934324B (en) Fungicidal (2-aryl-2-substituted)ethyl-1,2,4-triazoles
DE69017971D1 (de) Biozide Verbindungen.
ZA91315B (en) Fungicidal active compound combinations
MX9207407A (es) Mejora de la biodisponibilidad de agentes terapeuticos proteoliticamente labiles.
ZA929405B (en) 2-(Heteroaryloxyphenoxy) alkylsulfonates useful as herbicidal agents.
ZA91314B (en) Fungicidal active compound combinations
GB9024873D0 (en) Fungicidal compounds
DE69016122D1 (de) Biozide Verbindungen.
IT1215344B (it) Procedimento per la preparazione di composti ad attivita' anti-ulcera.
ZA92816B (en) Benzimidazole compounds.
USD273889S (en) Bathtub leg
OA09328A (en) "Heterocyclic compounds".
USD277726S (en) Riser stabilizer for sprinkler system pipes
IT1215960B (it) Procedimento per la carbocementazione di un pezzo di acciaio.